Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
Why Astra won’t find bladder cancer domination easy
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
Macrocycle goes full Circle
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
